The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Elanco expects Befrena to launch in the US in the first half of 2026
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Jaypirca is making waves in the fight against B-cell malignancies
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Subscribe To Our Newsletter & Stay Updated
